Developments Pfizer to acquire Trillium Therapeutics to expand immuno-oncology therapies Pfizer (NYSE:PFE) entered into a definitive agreement to acquire Trillium Therapeutics (NASDAQ, TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. ... August 23, 2021